Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Characterization of anti-porcine epidemic diarrhea virus neutralizing activity in mammary secretions

Qinye Song,1, Suzanne Stone, Donna Drebes, Laura L. Greiner, Cheryl M.T. Dvorak, Michael P. Murtaugh

A R T I C L E   I N F O
Article history:
Received 6 March 2016
Received in revised form 1 June 2016
Accepted 2 June 2016
Available online 7 June 2016

Keywords:
PEDV
Neutralizing activity
Colostrum and milk
Dynamics
Anti-PEDV IgA
Correlation

A B S T R A C T
Porcine epidemic diarrhea virus (PEDV) causes a severe clinical enteric disease in suckling neonates with up to 100% mortality, resulting in devastating economic losses to the pork industry in recent years. Maternal immunity via colostrum and milk is a vital source to neonates of passive protection against diarrhea, dehydration and death caused by PEDV. Comprehensive information on neutralizing activity (NA) against PEDV in mammary secretions is critically important for assessing the protective capacity of sows. Therefore, the objectives of this study were to characterize anti-PEDV neutralizing activity in mammary secretions. Anti-PEDV NA was present in colostrum, milk and serum from PEDV-infected sows as determined both by immunofluorescence and ELISA-based neutralizing assays, with neutralization levels higher in colostrum and milk than in serum. The highest NA was observed in colostrum on day 1, and decreased rapidly in milk at day 3, then gradually declined from day 3 to day 19 post-farrowing. Notably, the NA in mammary secretions showed various patterns of decline over time of lactation that may contribute to variation in sow protective capacities. The kinetics of NA decline were associated with total IgA and IgG antibody levels. Neutralizing activity significantly correlated with specific IgA primarily to spike domain 1 (S1) and domain 2 (S2) proteins of PEDV rather than to specific IgG in colostrum. Subsequently, the NA in milk was mainly related to specific IgA to S1 and S2 during lactation.

© 2016 Elsevier B.V. All rights reserved.

1. Introduction
Porcine epidemic diarrhea (PED), an acute and highly contagious enteric disease, is characterized by watery diarrhea, vomiting, dehydration, and high mortality in suckling piglets, especially in 7–10-day-old piglets (Li et al., 2012; Pijpers et al., 1993). The disease was first recorded in England in 1971 and spread to other European and Asian countries (Li et al., 2012; Park et al., 2013; Wood, 1977). Since late 2010, PED prevalence with high morbidity (90–100%) and mortality (70–100%) in suckling pigs has become more clinically frequent, and more severe than the historical clinical symptoms in China (Chen et al., 2011; Li et al., 2012; Yang et al., 2013). The outbreaks of PED suddenly occurred in April 2013 and spread through the pork industry across the United States (US) (Anon, 2014; Chen et al., 2014; Cima, 2013; Stevenson et al., 2013; Vlasova et al., 2014).
PEDV, a member of the genus Alphacoronavirus within the family Coronaviridae, is a positive-sense single-stranded, enveloped RNA virus (Pensaert and de Bouck, 1978). The 28 kb genome encodes four major structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N) (Kocherhans et al., 2001; Song and Park, 2012). The S protein of PEDV can be divided into domain 1 (S1) and domain 2 (S2) (Lee et al., 2010; Oh et al., 2014). It is a pivotal surface glycoprotein involved in virus attachment, entry and induction of neutralizing antibodies in the natural host (Cruz et al., 2008; Sun et al., 2008). The N protein is the most abundant viral protein in infected cells, is associated with the viral RNA genome, and may be important for induction of cell-mediated immunity (CMI) (Saif, 1993).
PEDV causes severe enteric disease in suckling pigs, but milder disease in older weaned pigs (Annamalai et al., 2015; Chen et al., 2014; Madison et al., 2014; Stevenson et al., 2013), similar to another enteric coronavirus, transmissible gastroenteritis virus (TGEV) (Moon et al., 1973; Norman et al., 1973). Therefore, maternal vaccines to induce lactogenic immunity and their transmission
to suckling neonates via colostrum and milk are pivotal for early passive protection (Chattaha et al., 2015; Wesley and Lager, 2003). Inoculations with PEDV virulent isolates, killed or attenuated strains induce specific mucosal and systemic immune responses in sows (Goede et al., 2015; Ouyang et al., 2015). The specific neutralizing antibodies (NA) were presented in colostrum, milk and serum after attenuated PEDV was orally or intramuscularly administered to late-term pregnant sows (Kweon et al., 1999; Ouyang et al., 2015). Lactogenic immunity, based on the presence of specific NA, can decrease the mortality of neonatal piglets or prevent death after challenge with wild-type PEDV (Goede et al., 2015; Kweon et al., 1999; Song et al., 2007).

Considering that maternal antibody plays pivotal roles in protecting neonates from enteric infections, we characterized neutralizing activity against PEDV in colostrum, milk and serum of sows after farrowing, the dynamics of the neutralizing activity in milk during lactation, and correlations between the neutralizing activity and specific antibodies to PEDV-S1, -S2 and -N proteins.

2. Materials and methods

2.1. Cells and virus

Vero-81 cells were cultured in complete medium containing 10% heat inactivated fetal bovine serum, 0.1 mM non-essential amino acids (Sigma), and 50 μg/mL gentamycin sulfate (Lonza) in Minimal Essential Medium (MEM, Sigma) at 37°C in a humidified atmosphere with 5% CO2. PEDV strain 13-019349 (Genbank ID: KF267450), isolated from PEDV-infected fecal samples at the National Veterinary Services Laboratories, Ames IA, was propagated in Vero-81 cells with complete medium containing 2.5 μg/mL trypsin, and 10% trypsin-free phosphate broth solution (Sigma). Removal of trypsin from the maintenance media resulted in reduced infection, as reported previously (Li et al., 2012). Virus stocks of 2.5 × 10^5 TCID50/mL or 1.4 × 10^10 viral genome copies per mL were collected and stored at −80°C until use.

2.2. Sample collection

A midwestern United States sow farm was diagnosed with a PEDV outbreak and a planned exposure event occurred while weaned piglets were testing positive for PEDV by PCR. The planned exposure inoculum was prepared by humanely sacrificing piglets clinically affected with acute diarrhea, collecting intestinal contents and diluting in water. Two months after exposure of the entire herd, all weaned pigs tested negative for PEDV. Colostrum, milk and serum samples were collected from sows beginning one month later. Colostrum was harvested by hand massage within 24 h and milk at or after 3 days post-farrowing. Serum was collected by venipuncture in serum-separator tubes. PEDV antibody-negative colostrum, milk and serum were collected from sows at a farm without PEDV infection.

Colostrum and milk were incubated at 37°C for 30 min with 2.5 μg/mL rennet. The clear fluid was harvested and heat-inactivated for 30 min at 56°C. Alternatively, samples were refrigerated for 3 days to obtain an aqueous fraction that was heat-treated. Serum also was heat-inactivated. The treated samples were used immediately or stored at −40°C prior to testing.

2.3. Antigen production

PEDV RNA was extracted from a fecal sample containing isolate USA/Colorado/2013 (Genbank accession KF272920). PCR amplicons were obtained that contained open reading frames encoding N (sequence 26382-27701), S1 (sequence 20694-22844) and S2 (sequence 22860-24614). Amplicons were inserted into the pET25b vector (Novagen, Madison, WI) by In-Fusion cloning (TaKaRa) and transformed into E. coli for expression and purification as previously described (Dvorak et al., 2016; Johnson et al., 2007; Puvanendiran et al., 2011). Inserts of recombinant plasmids were sequenced to confirm their identities. Recombinant protein quality was assessed by SDS-gel electrophoresis (Fig. 1).

2.4. ELISA

96-well plate wells (Corning, NY) were coated with 0.1 μg of recombinant PEDV proteins, S1, S2 or N, in 50 mM carbonate buffer (pH 9.6), and incubated at 4°C overnight. Plates were washed three times with phosphate-buffered saline (PBS), pH 7.4, containing 0.05% Tween-20 (PBST) at room temperature (ELx405 Microplate Washer, Bio-Tek Instrument Inc.). Blocking buffer (PBST with 5% non-fat dry milk) was added for 2 h, washed, and diluted samples (colostrum, milk or serum) and negative control (1:50) were added in duplicate for 1 h at room temperature. After washing, horseradish peroxidase (HRP) conjugated goat anti-pig IgG (Bethyl Labs) diluted 1:100,000, was added for 1 h. After plates were washed, tetramethylbenzidine (TMB) peroxidase substrate with H2O2 was added to each well to develop in the dark for 15 min. The reaction was stopped with 1 M phosphoric acid. Optical density (OD) was measured with an ELISA-spectrophotometer (Bio-Tek) at 450 nm.

Total IgG and IgA antibody levels in milk were determined by isotype-specific ELISA using a standard curve (Bethyl Laboratories). In brief, diluted coating antibody (IgG or IgA) was added to each well for 1 h. Serially two-fold diluted standards and samples in duplicate were added and incubated for 1 h. After washing, HRP-conjugated detection antibody was added and incubated as described. Plates were washed and TMB Substrate Solution was added to each well. Plates were developed in the dark for 15 min and reactions stopped with phosphoric acid as described. Absorbance was measured on

---

**Fig. 1.** SDS polyacrylamide gel containing purified N, S1 and S2. Bands were visualized with Imperial protein stain (Thermo Scientific). The molecular weight standards were Kaleidoscope prestained proteins (BioRad). The predicted molecular weight of N is about 55 kD, but it runs anomalously on SDS gels.
the plate reader at 450 nm. The IgG or IgA concentration was calculated in unknown samples using the standard curve.

2.5. Immunoﬂuorescence assay (IFA) for neutralization activity

The colostrum, milk and serum were two-fold serially diluted in maintenance media and incubated with an equal volume of PEDV at a multiplicity of infection (MOI) of 0.01 for 1 h at 37 °C. One hundred μL of the sample-virus mixture was transferred to duplicate wells containing confluent Vero-81 cells in 96-well plates. Samples (colostrum, milk or serum), virus and blank controls were prepared at the same time. Plates were incubated for 1 h at 37 °C, washed gently, and pre-warmed maintenance media was added. Plates were incubated for 48 h at 37 °C in a 5% CO2 atmosphere. Plates were washed and fixed using ice-cold absolute methanol for 10 min at −20 °C. The methanol was removed, wells washed, and anti-PEDV N protein monoclonal antibody (SD6-29, Medgene Labs) was added at a dilution of 1:1000 for 1 h at 37 °C. Plates were washed and Alexa Fluor 488-conjugated goat anti-mouse IgG1 (Bethyl Laboratories) (1:1000) was then added and incubated for 45 min at 37 °C. Plates were washed and cells were stained with bisbenzimide (10 ng/mL) for 20 min and washed. The plates were examined and images were captured under an Olympus 1X70 inverted ﬂuorescence microscope.

2.6. ELISA-based neutralizing assay

The PEDV serum neutralization (SN) assay was performed essentially as described and explained (Li and Muir, 2012; Robinson et al., 2013). Milk and colostrum samples were serially diluted and incubated with PEDV at a multiplicity of infection (MOI) of 0.01 for 1 h at 37 °C. Confluent Vero-81 cell monolayers in 96-well plates were washed with PBS before mixtures of sample and virus, positive-control virus and blank controls were added in duplicate. After 1 h incubation at 37 °C, plates were washed and incubated at 37 °C in prewarmed media. After 24 h, plates were washed and fixed in 3.7% formaldehyde for 30 min, permeabilized with 0.1% Triton X-100 for 5 min, washed and blocked with 5% non-fat dry milk in 50 mM carbonate buffer, pH 9.5, for 1 h at 37 °C. Cells were treated with anti-PEDV N protein monoclonal antibody (SD6-29) (Medgene Lab, USA) diluted 1:1000 for 1 h at 37 °C, washed, and incubated with HRP-conjugated goat anti-mouse IgG heavy and light chains antibody (Bethyl Laboratories, USA) diluted 1:10 000. Plates were washed with PBST and developed using TMB development solution (KPL, USA). Reactions were stopped with 1 M phosphoric acid and absorbance was measured at 450 nm in a spectrophotometer (BioTek, USA). Percent inhibition of viral infection at each dilution was compared with virus only controls after background subtraction of absorbance from uninfected cells. Fifty percent neutralization titer was defined as reciprocal of the highest serum dilution for which 50% inhibition of infection was reached.

2.7. Statistical analysis

All data were expressed as the mean ± standard error of mean (SEM). Neutralizing antibody titers were converted into log10 and used in statistical analysis. SPSS 17.0 was employed for correlation analysis and a value of p < 0.05 was considered statistically significant.

3. Results

3.1. Neutralizing activities in serum, colostrum and milk

Presence of specific antibodies against PEDV-N, S1 and S2 proteins in serum, colostrum and milk conﬁrmed that test sows were previously infected. Fig. 2 shows that the relative level of anti-S2 IgG in serum was higher and less variable than anti-N IgG, and that the level of anti-S1 IgG was near the limit of detection. Anti-PEDV IgA antibodies in serum were insigniﬁcant (data not shown). The pattern of IgG reactivity in colostrum and milk was similar to that observed in serum, though with exceeding high levels of variation, particularly in milk, in which levels of anti-N and anti-S1 were undetectable in some sows. Quantitative comparison of IgG levels in serum, colostrum and milk was not feasible since sample dilutions needed to give results within the linear absorbance range of the ELISA varied greatly. Speciﬁcally, serum was diluted from 1:3000 to 1:10,000, colostrum from 1:100,000 to 1:1,000,000, and milk from 1:3000 to 1:250,000. Anti-PEDV IgA results differed notably from IgG results, with anti-S1 IgA most abundant in colostrum and anti-N substantially lower, and in milk anti-S1 and anti-S2 IgA were both high compared to anti-N-IgA (Fig. 2).

Validation of the PEDV neutralization assay in serum, colostrum and milk matrices was ﬁrst established by immunofluorescent visualization of infected Vero 81 cell monolayers. Typical ﬂuorescent images of infected monolayers are shown in Fig. 3. Addition of serially diluted milk from a previously infected sow showed solid inhibition, even at the highest dilution of 1:128. Similarly, colostrum and serum samples showed dilution-dependent inhibitory activity (Fig. 3). The ELISA-based neutralizing assay showed that 50% inhibition of viral infection was observed in serum at a dilutions of 1:128–1:256, in colostrum at 1:1600–1:3200, but with occasional samples >1:6400, and in milk at 1:800–1:1600 (Fig. 4A–C). These results indicated that colostrum and milk had higher levels of PEDV neutralizing activity than were present in serum, and also showed that variation among sows was higher than would be predicted from results using serum.

3.2. Temporal dynamics of neutralizing antibody secretion during lactation

Inhibition of PEDV infection was determined in colostrum and milk secretions from 37 sows over 19 days post-farrowing. Average neutralizing antibody titer was highest in colostrum collected on day 1 compared to milk collected on days 3, 12 and 19 post-parturition (P < 0.01). Average neutralizing titer in colostrum was 1:3220, declining to 1:1000 by day 3, then declining slowly to 1:560 by day 19 (Fig. 5 and Table 1). However, various declining trends of neutralizing antibody in milk were exhibited among different sows over time of lactation (Fig. 6A–F), and the neutralization of PEDV in
some sows became very low by day 12 after farrowing (Fig. 6C and E).

The dynamics of total IgG and IgA production in milk were measured from day 1 to day 19 post-farrowing by isotype-specific ELISA. Concentrations of both IgG and IgA were significantly higher in colostrum (day 1) than in milk (day 3–day 19) (p < 0.01). IgG levels continued to decline from day 3 to day 19 while IgA levels were maintained in milk at about 7 mg/mL (Table 1). These two trends were similar to that of neutralizing activity against PEDV, but the kinetics of IgA production paralleled neutralizing activity more closely than did IgG.

3.3. Correlations between neutralizing activity and antibodies to N, S1 and S2 proteins

Specific viral neutralization activity correlated significantly with specific IgA in milk to PEDV N, S1 and S2 protein rather than specific IgG at day 1 post-farrowing (Table 2). After day 1, the viral neutralization activity was mainly related to specific IgA to S1 and S2 over time of lactation.

4. Discussion

Maternal antibodies from sows inoculated or infected with enteric viruses such as PEDV or TGEV are vitally important for suckling neonates to obtain early passive protection via colostrum and milk (Chattha et al., 2015; Goede et al., 2015; Wesley and Lager, 2003). Specific IgA and IgG neutralizing antibodies in serum and colostrum appeared when the late-term pregnant sows were inoculated with an attenuated PEDV orally or intramuscularly (Ouyang et al., 2015; Paudel et al., 2014; Song et al., 2007). In this study, PEDV-specific neutralizing activity found in serum, colostrum and milk exhibited various levels of neutralizing activity in which the highest inhibition was in colostrum, then in milk, and last in serum, as observed previously (Paudel et al., 2014). This result emphasizes the importance of mammary secretions to suckling neonates to obtain early passive protection from PED.

PEDV-specific antibodies were observed in serum and oral fluids in sows from 1 to 6 months after infection, and the virus neutralization titers in serum persisted beyond 6 months (Ouyang et al., 2015). However, the characteristics of PEDV-specific neutralizing antibody responses in mammary secretions have not been characterized. We show that the virus neutralizing antibody titer and the levels of total IgG and IgA in colostrum at day 1 significantly exceeded those in milk at day 3, and declined progressively from

![Figure 3](image-url)
day 3 to day 19 after farrowing. Further analysis indicated that IgG levels continued to drop sharply from day 3 to day 19 while IgA declined slightly, more closely to the trend of virus neutralizing activities at the same time. This result indicated that IgA might play a more important role in virus neutralization especially after day 3 post-farrowing.

Various patterns of declining neutralizing activities were observed in sow milk over time of lactation. The various patterns of neutralizing antibody activity through lactation showed the complexity of lactogenic immunity, and might explain why feedback methods utilizing PEDV infected material have shown variable success in protection of litters from PED (R. Morrison, personal communication). It still remains a challenge to achieve uniformity of lactogenic immunity in herds against PEDV infection.

PEDV S glycoprotein (S1 and S2 domains) containing B cell neutralizing epitopes can stimulate the production of viral neutralizing antibodies (Cruz et al., 2008; Sun et al., 2008). The N protein may be important for induction of cell-mediated immunity and be able to effectively facilitate the mucosal and systemic immune responses induced by S1 protein (Liu et al., 2012; Saif, 1993). In addition, M protein plays an important role in viral assembly, and it contains a conserved linear B-cell epitope (Andrt et al., 2010; Zhang et al., 2012). Here, further analyses of the correlations of PEDV neutralizing activities and specific antibody isotypes, IgG and IgA to PEDV S1, S2 or N proteins in mammary secretions during lactation indicated that the specific anti-S1, -S2 and -N IgG did not correlate significantly with viral neutralizing activity in milk. However, the neutralizing activities were dominated by IgA to S1 and S2 proteins in colostrum on day 1 post-farrowing. Subsequently, anti-S1 and anti-S2 IgA in milk played a vital role in viral neutralization. The results demonstrated that PEDV neutralizing activities in mammary secretions, within the limitations of the proteins examined, i.e. S1, S2, and N, were correlated with specific antibodies to structural proteins of PEDV, principally anti-S1 and anti-S2 IgA, in milk.

The ELISA-based PEDV neutralization assay was used because it is a more direct measure of an effect on infection since assays based on plaque formation also depend on viral cytopathology, are more labor and time intensive, and can be affected by operator experience. The use of 50% reduction as the readout in place of a focus-forming or plaque assay with 90% reduction enables optimization of key parameters, including MOI and testing of the percentage law (Andrewes and Elford, 1933; Brioen and Boeaye, 1985). The 50% endpoint for neutralization titers was used in place of 90% reduction in focus-forming units to gain information about the antibody reactivity independently of antigen concentration. Virus–antibody interactions can be modeled as antigen–antibody interactions that conform to the law of mass action as a reaction approaches equilibrium (Klasse and Sattentau, 2002; Reverberi and Reverberi, 2007; Tyrrell, 1953). Since neutralized and non-neutralized virus is in equilibrium at 50% inhibition of infectivity, mathematical modeling can be used to assess functional qualities of antibodies and antisera that have viral neutralizing activity, as has been shown in HIV, influenza virus, human adenovirus, equine infectious anemia virus, chimeric SIV/HIV, and Newcastle disease virus infections (Klasse and Moore, 1996; McEwan et al., 2012; Nishimura et al., 2002; Schwartz and Smith, 2014; Shingai et al., 2014; To et al., 2012; Tyrrell, 1953; Willey et al., 2010). Characterization of neutralization affinity, reaction kinetics, and avidity cannot be determined under more stringent conditions, such as at 90% inhibition, which are not at equilibrium. More stringent neutralization readouts may have value for diagnostic purposes or for studies in which there is background cross-reactivity such as with dengue virus (Roehrig et al., 2008). However, cross-reacting substances have not been reported to interfere with PEDV neutralization assays.
### Table 2
Correlations between neutralizing activities and isotype-specific antibodies to N, S1 and S2 proteins in colostrum and milk.

| Days post-farrowing | Ig     | OD<sub>450</sub> (n=37) | NA<sub>{Log}_{50}</sub> (n=37) | Correlation coefficient | P value  |
|---------------------|--------|--------------------------|--------------------------------|-------------------------|----------|
| 1                   | N IgG  | 1.215 ± 0.398            | 3.337 ± 0.406                  | 0.011                   | 0.951    |
|                     | S1 IgG | 0.701 ± 0.382            | 0.301                          |                         | 0.079    |
|                     | S2 IgG | 1.110 ± 0.313            | 0.174                          |                         | 0.318    |
| 1                   | N IgA  | 0.679 ± 0.280            | 0.460                          |                         | 0.003**  |
|                     | S1 IgA | 1.360 ± 0.453            | 0.450                          |                         | 0.007**  |
|                     | S2 IgA | 1.065 ± 0.336            | 0.455                          |                         | 0.006**  |
| 3                   | N IgG  | 0.363 ± 0.189            | 2.995 ± 0.399                  | 0.292                   | 0.111    |
|                     | S1 IgG | 0.943 ± 0.385            | 0.528                          |                         | 0.002**  |
|                     | S2 IgG | 0.610 ± 0.305            | 0.489                          |                         | 0.005**  |
| 12                  | N IgA  | 0.288 ± 0.184            | 2.769 ± 0.386                  | 0.346                   | 0.039*   |
|                     | S1 IgA | 0.709 ± 0.328            | 0.616                          |                         | 0.000**  |
|                     | S2 IgA | 0.496 ± 0.255            | 0.574                          |                         | 0.000**  |
| 19                  | N IgA  | 0.285 ± 0.142            | 2.748 ± 0.455                  | 0.159                   | 0.353    |
|                     | S1 IgA | 0.687 ± 0.335            | 0.375                          |                         | 0.024*   |
|                     | S2 IgA | 0.419 ± 0.208            | 0.420                          |                         | 0.011*   |

*or ** indicated that the correlation was significant at the 0.05 or 0.01 level (2-tailed).  
* Colostrum (day 1) and milk (days 1, 3, 12 and 19 post-farrowing) were collected from PEDV immune sows. Correlation was performed by comparing the neutralizing titer of each sample to the antigen- and isotype-specific ELISA value of the sample using SPSS 17.0.

---

**Fig. 6.** Various patterns of neutralizing activities in milk in Vero-81 cells by ELISA-based neutralizing assay. Milk collected on days 1, 3, 12 and 19 post-farrowing. A through F are the neutralization curves for each time point in 6 individual sows.

In summary, the data show that neutralizing antibody levels against PEDV are high but patterns of passive expression in colostrum and milk are variable over time in mammary secretions. Sow variability might help explain the inconsistent success...
of feedback methods to protect suckling neonates from clinical PED through maternal protection received from immune dams. Moreover, the kinetics of neutralizing antibody titers during lactation help explain the pivotal role of IgA in colostom and milk in suckling neonates to gain passive protection. The amount of neutralizing antibodies necessary for protection in piglets is unknown, and would be affected by titers, volume of milk ingested, antibody stability in the enteric environment, and possibly other variables that could be difficult to measure. Neutralizing activities in mammary secretions, which can be assessed and are mainly correlated with specific IgA antibodies to PEDV spike glycoprotein, may help guide vaccine design and immunological monitoring for PEDV.

Authors’ contributions

Qiye Song performed the cell culture and neutralization experiments, data analysis, and drafted the manuscript. SS designed and performed the ELISA, and analyzed the data. DD collected the samples, reviewed the manuscript and assisted in data analysis. LLG conceived the study with MPM, designed and monitored the animal studies, and assisted in writing. MPM conceived the study with LLG, analyzed data, edited and finalized the manuscript.

Competing interest

The authors declare that they have no competing interests.

Acknowledgements

This work was supported by the Cooperative State Research Service, U.S. Department of Agriculture, under project MIN-63-112, National Pork Board grant 14-175, the China Scholarship Council and the National Natural Science Foundation of China (31372441) to support QS, and Carthage Veterinary Services, Carthage, IL. DD was a DVM student in the College of Veterinary Medicine, University of Minnesota, sponsored by Carthage Veterinary Services on an internship. We thank Audrey Tseng, an undergraduate student at the University of Minnesota, for assistance in protein expression and purification.

References

Andrewes, C.H., Elford, W.J., 1933. Observations on anti-phase sera. I. The percentage law. Br. J. Exp. Pathol. 14 (6), 367–376.

Amannalai, T., Saif, J.L., Lee, Z., Jung, K., 2015. Age-dependent variation in innate immune responses to porcine epidemic diarrhea virus infection in suckling versus weaned pigs. Vet. Immunol. Immunopathol. 168 (3-4), 193–202.

Anon, 2014. In: U.S.D.O. Agriculture (Ed.), Swine Enteric Coronavirus Disease Testing Summary Report, July 24, 2014. US Government Printing Office, Washington, DC, pp. 1–33.

Arndt, A.L., Larson, B.J., Hogue, B.G., 2010. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. J. Virol. 84 (21), 11418–11428.

Brieno, P., Boeae, A., 1985. Poliovirus neutralization and the percentage law. Brief report. Arch. Virol. 83 (1-2), 105–111.

Chhatra, K.S., Roth, J.A., Saif, J.L., 2015. Strategies for design and application of enteric viral vaccines. Annu. Rev. Anim. Biosci. 3, 375–395.

Chen, J., Wang, C., Shi, H., Qiu, H.J., Liu, S., Shi, D., Zhang, X., Feng, L., 2011. Complete genome sequence of a Chinese virulent porcine epidemic diarrhea virus strain. J. Virol. 85 (21), 11538–11539.

Chen, Q., Li, G., Stasko, J., Thomas, J.T., Stensland, W.R., Pillatzi, A.E., Gauger, P.C., Schwartz, K.J., Madson, D., Yoon, K.J., Stevenson, G.W., Burrough, E.R., Harmon, K.M., Main, R.G., Zhang, J., Yoon, J.K., 2014. Pathogenesis of porcine epidemic diarrhea virus isolate (US/Iowa/18984/2013) in 3-week-old weaned pigs. Vet. Microbiol. 174 (1-2), 60–68.

McEwan, W.A., Hauer, F., Williams, C.R., Bidgood, S.R., Mallory, D.L., Crowther, R.A., James, L.C., 2012. Regulation of virus neutralization and the persistent fraction by TRIM21. J. Virol. 86 (16), 8482–8491.

Moon, H.W., Norman, J.O., Lambert, G., 1973. Age dependent resistance to transmissible gastroenteritis of swine (TGE). I. Clinical signs and some mucosal changes in small intestinal Can. J. Comp. Med. 37 (2), 157–166.

Nishimura, Y., Igarashi, T., Haigwood, N., Sadjadpour, R., Plisika, R.J., Buckler-White, A., Shihata, R., Martin, M.A., 2002. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titer neutralizing antibodies. J. Virol. 76 (5), 2123–2130.

Norman, J.O., Lambert, G., Moon, H.W., Stark, S.L., 1973. Age dependent resistance to transmissible gastroenteritis of swine (TGE). II. Coronavirus titer in tissues of pigs after exposure. Can. J. Comp. Med. 37 (2), 167–170.

Oh, J., Lee, K.W., Choi, H.W., Lee, C., 2014. Immunogenicity and protective efficacy of recombinant S1 domain of the porcine epidemic diarrhea virus spike protein. Arch. Virol. 159 (11), 2977–2987.

Ouyang, K., Shyu, D.L., Dhakal, S., Himmerath, N., Jain, B., Lakshmanappa, Y.S., Guo, R., Ransburgh, R., Bondra, K.M., Gauger, P., Zhang, J., Specht, T., Gilbertie, A., Minton, W., Fang, Y., Renukaardhy, G.J., 2015. Evaluation of humoral immune status in porcine epidemic diarrhea virus (PEDV) infected sows under field conditions. Vet. Res. 46 (1), 140.

Park, S.J., Song, D.S., Park, B.K., 2013. Molecular epidemiology and phylogenetic analysis of porcine epidemic diarrhea virus (PEDV) field isolates in Korea. Arch. Virol. 158 (7), 1533–1541.

Paudel, S., Park, J.E., Kang, H., Hyun, B.H., Yang, D.G., Shin, H.J., 2014. Evaluation of antibody response of killed and live vaccines against porcine epidemic diarrhea virus in a field study. Vet. Q. 34 (4), 194–200.

Pensaert, M.B., de Bouck, P., 1978. A new coronavirus-like particle associated with diarrhea in swine. Arch. Virol. 58 (3), 243–247.

Pijpers, A., van Nieuwstadt, A.P., Terzstra, C., Verheijden, J.H., 1993. Porcine epidemic diarreha virus as a cause of persistent diarrheea in a herd of breeding and finishing pigs. Vet. Rec. 132 (6), 129–131.

Puvanendiran, S., Stone, S., Yu, W., Johnson, C.R., Abrante, J., Jimenez, L.G., Griggs, T., Harms, C., Wagner, B., Maun, M.P., 2011. Absence of porcine coronavirus type 1 (PCV1) and high prevalence of PCV2 exposure and infection in swine finisher herds. Virus Res. 157 (1), 92–98.

Reverberi, R., Reverberi, L., 2007. Factors affecting the antigen-antibody reaction. Blood Transfus. 5 (4), 227–240.

Robinson, S.R., Figueredo, M.C., Abrante, J.E., Maun, M.P., 2013. Immune response to ORF5a protein immunization is not protective against porcine reproductive and respiratory syndrome virus infection. Vet. Microbiol. 164 (3–4), 281–285.

Roeheg, J.T., Hornbach, J., Barrett, A.D., 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 21 (2), 123–132.

Saif, J.L., 1993. Coronavirus immunogens. Vet. Microbiol. 37 (3–4), 285–297.
Schwartz, E.J., Smith, R.J., 2014. Identifying the conditions under which antibodies protect against infection by equine infectious anemia virus. Vaccines (Basel) 2 (2), 397–421.

Shingai, M., Donau, O.K., Plishka, R.J., Buckler-White, A., Mascola, J.R., Nabel, G.J., Nason, M.C., Montefiori, D., Moldt, B., Poignard, P., Diskin, R., Bjorkman, P.J., Eckhaus, M.A., Klein, F., Mouquet, H., Cetrulo Lorenzi, J.C., Gazzinian, A., Burton, D.R., Nussenzweig, M.C., Martin, M.A., Nishimura, Y., 2014. Passive transfer of modest titers of broad and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211 (10), 2061–2074.

Song, D., Park, B., 2012. Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines. Virus Genes 44 (2), 167–175.

Song, D.S., Oh, J.S., Kang, B.K., Yang, J.S., Moon, H.J., Yoo, H.S., Jang, Y.S., Park, B.K., 2007. Oral efficacy of Vero cell attenuated porcine epidemic diarrhoea virus DR13 strain. Res. Vet. Sci. 82 (1), 134–140.

Stevenson, G.W., Hoang, H., Schwartz, K.J., Burrough, E.R., Sun, D., Madison, D., Cooper, V.L., Pilatzi, A., Gauger, P., Schmitt, R.J., Koster, L.G., Killian, M.L., Yoon, K.J., 2013. Emergence of Porcine epidemic diarrhoea virus in the United States: clinical signs, lesions, and viral genomic sequences. J. Vet. Diagn. Invest. 25 (5), 649–654.

Sun, D., Feng, L., Shi, H., Chen, J., Cui, X., Chen, H., Liu, S., Tong, Y., Wang, Y., Tong, G., 2008. Identification of two novel B cell epitopes on porcine epidemic diarrhoea virus spike protein. Vet. Microbiol. 131 (1–2), 73–81.

To, K.K., Zhang, A.J., Hung, I.F., Xu, T., Ip, W.C., Wong, R.T., Ng, J.C., Chan, J.F., Chan, K.H., Yuen, K.Y., 2012. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin. Vaccine Immunol. 19 (7), 1012–1018.

Tyrrell, D.A., 1953. Neutralization of viruses by homologous immune serum. II. Theoretical study of the equilibrium state. J. Exp. Med. 97 (6), 863–870.

Vlasova, A.N., Marthaler, D., Wang, Q., Culhane, M.R., Rossow, K.D., Rovira, A., Collins, J., Saif, L.J., 2014. Distinct characteristics and complex evolution of PEDV strains, North America, May 2013–February 2014. Emerg. Infect. Dis. 20 (10).

Wesley, R.D., Lager, K.M., 2003. Increased litter survival rates, reduced clinical illness and better lactogenic immunity against TGEV in gilts that were primed as neonates with porcine respiratory coronavirus (PRCV). Vet. Microbiol. 95 (3), 175–186.

Willey, R., Nason, M.C., Nishimura, Y., Follmann, D.A., Martin, M.A., 2010. Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bi assay. AIDS Res. Hum. Retrovirol. 26 (1), 89–98.

Wood, E.N., 1977. An apparently new syndrome of porcine epidemic diarrhoea. Vet. Rec. 100 (12), 243–244.

Yang, X., Huo, J.Y., Chen, L., Zheng, F.M., Chang, H.T., Zhao, J., Wang, X.W., Wang, C.Q., 2013. Genetic variation analysis of reemerging porcine epidemic diarrhoea virus prevailing in central China from 2010 to 2011. Virus Genes 46 (2), 337–344.

Zhang, Z., Chen, J., Shi, H., Chen, X., Shi, D., Feng, L., Yang, B., 2012. Identification of a conserved linear B-cell epitope in the M protein of porcine epidemic diarrhoea virus. Virol. J. 9, 225.